Hims & Hers stock slips premarket after FDA “illegal copycat drugs” warning clouds $49 Wegovy-style pill
Hims & Hers Health shares fell 3.8% to $23.48 premarket Friday after the FDA signaled a crackdown on copycat drugs and Novo Nordisk threatened legal action over Hims’ compounded semaglutide pill. The stock had surged Thursday before closing down 4% amid volatility and regulatory concerns.